|
| Status |
Public on May 30, 2011 |
| Title |
Patient 451 control |
| Sample type |
RNA |
| |
|
| Source name |
Patient 451 control
|
| Organism |
Homo sapiens |
| Characteristics |
tumor type: chronic lymphocytic leukemia
tissue type: whole peripheral blood
therapeutic agent: SPC2996
dose group: 6mg per kg
time point: pre-tx
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Whole PB samples were collected at the designated time points and stored at -80°C for up to 3 years in the PAXgene blood stabilizing system. After thawing, RNA was extracted employing the QIAGEN PAXgene extraction kit and repurified using the Rneasy MinElute Cleanup kit (QIAGEN).
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
|
| |
|
| Hybridization protocol |
Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human Genome U133Plus_2.0 Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
|
| Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 (G7 update).
|
| Description |
Gene expression data from whole PB samples from CLL patient collected before the first infusion of SPC2996
|
| Data processing |
The data were analyzed with GCOS 1.4 using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 1000.
|
| |
|
| Submission date |
Mar 09, 2011 |
| Last update date |
May 30, 2011 |
| Contact name |
Ludger Klein-Hitpass |
| E-mail(s) |
[email protected]
|
| Phone |
+49 201 723 85552
|
| Organization name |
Institut fuer Zellbiologie
|
| Department |
Universitaetsklinikum
|
| Lab |
BioChip Lab
|
| Street address |
Virchowstr. 173
|
| City |
Essen |
| ZIP/Postal code |
D-45122 |
| Country |
Germany |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE27858 |
The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia |
|
